Regado Biosciences to Present at the 3rd Annual Canaccord Adams Cardiovascular Conference on November 10, 2009
* Reuters is not responsible for the content in this press release.
Regado Biosciences to Present at the 3rd Annual Canaccord Adams Cardiovascular Conference on November 10, 2009 BASKING RIDGE, N.J., Nov. 3 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that David J. Mazzo, Ph.D., President and Chief Executive Officer, will be presenting at the 3rd Annual Canaccord Adams Cardiovascular Conference at the Nikko Hotel in San Francisco, California. Dr. Mazzo's presentation scheduled for Tuesday, November 10, 2009 at 1:30 PM (PST), will include an overview of the Company's pipeline with emphasis on the lead development program, the anticoagulant system, REG1. This conference will feature myriad companies targeting cardiovascular disease including small- to mid-cap public companies as well as emerging late-stage private companies. ABOUT REGADO BIOSCIENCES Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine. ABOUT REG1 and REG2 Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006. REG1, presently in phase 2b clinical trials, is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention. REG2, Regado's second product candidate, consists of a subcutaneously administered formulation of RB006 paired with the IV bolus formulation of RB007. REG2 is currently undergoing phase 1 clinical testing and is intended for use in venous thrombosis indications ABOUT APTAMERS RB006 is a member of a class of compounds called aptamers. Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein. A key unique feature of aptamers derives from the fact that they are formed from nucleic acids. As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing it biologic effects. More information can be found at http://www.regadobio.com SOURCE Regado Biosciences Ellen McDonald, Chief Business Officer, Regado Biosciences, +1-908-580-2113, emcdonald@regadobio.com
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters